DrugPatentWatch Database Preview

Loxapine succinate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for loxapine succinate and what is the scope of loxapine succinate freedom to operate?

Loxapine succinate is the generic ingredient in two branded drugs marketed by Elite Labs Inc, Lannett Co Inc, Mylan, Watson Labs, and Actavis Labs Ut Inc, and is included in eight NDAs. Additional information is available in the individual branded drug profile pages.

There are eight drug master file entries for loxapine succinate. Nine suppliers are listed for this compound.

Summary for loxapine succinate

US Patents:	0
Tradenames:	2
Applicants:	5
NDAs:	8
Drug Master File Entries:	8
Suppliers / Packagers:	9
Bulk Api Vendors:	54
Clinical Trials:	1
Patent Applications:	1,728
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for loxapine succinate
DailyMed Link:	loxapine succinate at DailyMed

Synonyms for loxapine succinate

13-CHLORO-10-(4-METHYLPIPERAZIN-1-YL)-2-OXA-9-AZATRICYCLO[9.4.0.0(3),?]PENTADECA-1(11),3(8),4,6,9,12,14-HEPTAENE; BUTANEDIOIC ACID

1977-10-2 (Parent)

2-Chloro-11-(4-methyl-1- piperazinyl)-dibenz[b,f][1,4]- oxazepine succinate

2-Chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine succinate (1:1)

2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine, Succinate

2-chloro-11-(4-methyl-1-piperazinyl)dibenzo[b,f][1,4]oxazepine succinate

27833-64-3

833L643

AC1L2G38

AC1Q5VQU

AKOS015994711

AOB5330

AZ-004

AZ-104

BIL2251

Butanedioic acid, compd. with 2-chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine (1:1)

Butanedioic acid, compd. with 2-chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine (1:1)

butanedioic acid; 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine

butanedioic acid;8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine

C-54162

C22H24ClN3O5

CAS-27833-64-3

CCG-39497

CCRIS 1917

CHEBI:6549

CHEMBL1201155

CL 71563

CL-71563

Cloxazepin

CPD000058470

CS-4285

CTK4G0318

D00794

Daxolin

DSSTox_CID_25227

DSSTox_GSID_45227

DSSTox_RID_80764

DTXSID3045227

EINECS 248-682-0

EU-0100720

FT-0653022

HMS1568K06

HMS1922L14

HMS2051E05

HMS2093N20

HMS2095K06

HMS2232N05

HMS3262O21

HMS3374F02

HMS3393E05

HMS3652O10

HY-17390A

KS-1083

Lederle

Lopac-L-106

Loxapac

Loxapine (succinate)

Loxapine succinate (USP)

Loxapine succinate [USAN:USP]

Loxapine succinate [USAN]

Loxapine succinate salt

Loxapine succinate salt, solid

Loxapine succinate, United States Pharmacopeia (USP) Reference Standard

Loxapine, Succinate

Loxapine,succinate

Loxapinesuccinatesalt

Loxipine Succinate

Loxitane (TN)

LP00720

LS-147408

MFCD00069298

MLS000069383

MLS000758291

MLS001146961

MLS001401432

MLS002222201

MolPort-003-666-776

NC00011

NCGC00016160-01

NCGC00016160-02

NCGC00016160-03

NCGC00016160-04

NCGC00016160-05

NCGC00021145-11

NCGC00094068-01

NCGC00094068-02

NCGC00094068-03

NCGC00261405-01

NSC-759578

NSC759578

O287

Opera_ID_1518

Pharmakon1600-02300242

PL001478

Prestwick_304

REGID_for_CID_71399

s4086

SAM001247061

SCHEMBL41643

SMR000058470

SPECTRUM2300242

Staccato-loxapine

Succinic acid, compd. with 2-chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine (1:1)

Succinic acid, compound with 2-chloro-11-(4-methylpiperazin-1-yl)dibenz(b,f)(1,4)oxazepine (1:1)

Tox21_110311

Tox21_110311_1

Tox21_500720

UNII-X59SG0MRYU

VA11204

VU0239541-8

W-107092

X59SG0MRYU

ZX-AFC001324

US Patents and Regulatory Information for loxapine succinate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan	LOXAPINE SUCCINATE	loxapine succinate	CAPSULE;ORAL	076762-003	Nov 1, 2004	AB	RX	No	No
Lannett Co Inc	LOXAPINE SUCCINATE	loxapine succinate	CAPSULE;ORAL	090695-001	Sep 26, 2011	AB	RX	No	No
Actavis Labs Ut Inc	LOXITANE	loxapine succinate	CAPSULE;ORAL	017525-004	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Mylan	LOXAPINE SUCCINATE	loxapine succinate	CAPSULE;ORAL	076762-002	Nov 1, 2004	AB	RX	No	No
Actavis Labs Ut Inc	LOXITANE	loxapine succinate	TABLET;ORAL	017525-008	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for loxapine succinate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Actavis Labs Ut Inc	LOXITANE	loxapine succinate	CAPSULE;ORAL	017525-001	Approved Prior to Jan 1, 1982
Actavis Labs Ut Inc	LOXITANE	loxapine succinate	CAPSULE;ORAL	017525-003	Approved Prior to Jan 1, 1982
Actavis Labs Ut Inc	LOXITANE	loxapine succinate	CAPSULE;ORAL	017525-002	Approved Prior to Jan 1, 1982
Actavis Labs Ut Inc	LOXITANE	loxapine succinate	CAPSULE;ORAL	017525-004	Approved Prior to Jan 1, 1982